Indivina (Medroxyprogesterone Acetate, Estradiol Valerate)

Medroxyprogesterone acetate, together with estradiol valerate, suppresses the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, preventing ovulation. The progestogen also thickens cervical mucus and alters the endometrium, creating an environment that is unfavorable for fertilisation and implantation.

The specific dose and regimen of Indivina are determined by the prescribing healthcare professional based on the patient’s medical history and treatment goals. Patients should follow the prescriber’s instructions and not alter the dosing schedule on their own.

Indivina is intended for use as a contraceptive and should not be taken during pregnancy. If pregnancy occurs, the medication should be discontinued. Safety during breastfeeding has not been fully established; clinicians usually advise caution and may recommend alternative methods.

To order Indivina, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Indivina contains medroxyprogesterone acetate and estradiol valerate, which differ from many combined pills that use ethinyl‑estradiol and various progestins. This formulation may offer a more natural estrogen component and a distinct progestogenic profile, but efficacy and safety are comparable when used as directed.

Indivina tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Indivina is taken orally, usually once daily at the same time each day, as directed by the prescriber. The tablets are swallowed with water and should be started on the first day of the menstrual period or as instructed in the prescribing information.

The most serious risks include venous thromboembolism, arterial thrombosis (such as heart attack or stroke), severe hypertension, and liver dysfunction. Patients should be aware of symptoms like unexplained leg pain, chest discomfort, severe headache, or yellowing of the skin and seek immediate medical attention.

Indivina is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active or past breast cancer, severe liver disease, or in smokers over 35 years of age. It should also be avoided during pregnancy and in individuals known to be allergic to any component of the formulation.